Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 5/20 | 0.42 |
| ▸ | SYK | P43405 | 10/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 4/20 | 0.39 |
| ▸ | ZAP70 | P43403 | 3/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16159453 | 0.89 | PDK2 (0.35) | RAB9APDK2SYKPDPK1SRC | |
| SCHEMBL16159440 | 0.89 | PDPK1 (0.42) | RAB9APDK2SYKPDPK1SRC | |
| SCHEMBL16159492 | 0.84 | PDPK1 (0.49) | PDK2PDPK1LOXL2 | |
| SCHEMBL16159436 | 0.84 | RAB9A (0.41) | RAB9APDK2SYKPDPK1SRC | |
| SCHEMBL16159313 | 0.84 | PDPK1 (0.51) | RAB9APDK2PDPK1LOXL2 | |
| SCHEMBL14580664 | 0.83 | PDK2 (0.48) | RAB9APDK2 | |
| SCHEMBL16159143 | 0.82 | RAB9A (0.40) | RAB9APDK2SYKPDPK1HSP90AA1 | |
| SCHEMBL16159692 | 0.79 | RAB9A (0.53) | RAB9ASYKPDPK1SRCZAP70 | |
| SCHEMBL16159752 | 0.79 | CYP2A6 (0.44) | RAB9APDK2SYKPDPK1LOXL2 | |
| SCHEMBL17116829 | 0.78 | PDK2 (0.52) | RAB9APDK2CDK2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160118598-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | JNC CORPORATION (JP) | 2016-04-28 | — | — | US | disclosed |
| US-20160118598-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | JNC CORPORATION (JP) | 2016-04-28 | — | — | US | disclosed |
| WO-2014163173-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | JNC株式会社 (JP) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160118598-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | HVCN1, VDAC1, SLC26A3 | RAB9A 3067/4885PDK2 2391/4885SYK 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.